23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection...
20:23 , Jul 20, 2018 |  BC Week In Review  |  Company News

Insilico, A2A launch Consortium.AI to develop candidates for rare orphan diseases

Insilico Medicine Inc. (Baltimore, Md.) and A2A Pharmaceuticals LLC (Chappaqua, N.Y.) partnered to launch Consortium.AI, a company that will use artificial intelligence to develop small molecules for rare Orphan diseases including Duchenne muscular dystrophy (DMD)....
22:11 , Jun 1, 2018 |  BioCentury  |  Emerging Company Profile

Scratching the surface

Oppilotech Ltd. is using computational modeling to develop first-in-class compounds that can permeate the lipopolysaccharide layer of the outer cell membrane of Gram-negative bacteria to potentiate existing antibiotics. Marketed polymyxins are used to disrupt the...
16:20 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas; pneumonia...
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
07:00 , Aug 22, 2016 |  BioCentury  |  Emerging Company Profile

Metal smithing

Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets. Forge's lead program...